What question did this study set out to answer?

The study aims to assess the impact of beta-blockers on birth weight in pregnant women with long QT syndrome or Marfan syndrome.

February 9, 2026

Impact of β-Blockers on the Risk of Low-Birth-Weight Infants in Women with Long QT Syndrome or Marfan Syndrome: A Single-Center Retrospective Study from 2008 to 2022 in a Tertiary Care Center.

Key Points

The study aims to assess the impact of beta-blockers on birth weight in pregnant women with long QT syndrome or Marfan syndrome.
Retrospective analysis conducted at a tertiary care center
Participants included pregnant women with long QT syndrome or Marfan syndrome
Matched controls were used to reduce confounding factors related to cardiac conditions
Beta-blocker use was linked to significantly lower birth weight in infants
Higher rates of fetal growth restriction/small for gestational age were observed
Increased incidences of neonatal bradycardia were noted

Abstract

To our knowledge, this is the first study specifically focusing on β-blocker use in pregnant women with LQTS or MFS and structurally normal hearts, using matched controls to minimize confounding by underlying cardiac disease. β-Blocker use-mainly nadolol and bisoprolol-was associated with significantly lower birth weight and higher rates of FGR/SGA and neonatal bradycardia. Our findings support the continuation of β-blocker therapy when clinically indicated, combined with careful fetal growth monitoring and targeted neonatal surveillance.

Demander à l'IA

Bookmark

View Full Paper